Akouos Inc. (AKUS): Price and Financial Metrics
AKUS Price/Volume Stats
| Current price | $13.29 | 52-week high | $13.60 |
| Prev. close | $13.15 | 52-week low | $2.32 |
| Day low | $13.16 | Volume | 1,790,400 |
| Day high | $13.33 | Avg. volume | 344,411 |
| 50-day MA | $10.65 | Dividend yield | N/A |
| 200-day MA | $5.54 | Market Cap | 490.88M |
AKUS Stock Price Chart Interactive Chart >
Akouos Inc. (AKUS) Company Bio
Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna in 2017 and is headquartered in Boston, MA.
Latest AKUS News From Around the Web
Below are the latest news stories about AKOUOS INC that investors may wish to consider to help them evaluate AKUS as an investment opportunity.
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. |
Lilly and Akouos Announce Expiration of Akouos Tender OfferEli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockh |
10 Most Promising Gene Therapy Companies to WatchIn this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […] |
Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss w |
The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVieJ&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog. |
AKUS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -8.97% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -57.14% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...